Stockhead on MSN21h
Neurizon files key IND application with US FDA for motor neurone disease drug
Pending FDA clearance of the IND application, Neurizon said it anticipated Massachusetts General Hospital filing a protocol ...
Neurizon Therapeutics Moves Forward with ALS Trial
Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
Stockhead on MSN1d
Positive interim study results for Neurizon’s motor neurone disease drug
Neurizon Therapeutics has reported a positive interim eight-month update on its ongoing 12-month open-label extension (OLE) ...
FOX40 News29d
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding protein 43 (TDP-43), a key pathological feature of ALS, and the ability of NUZ ...
Neurizon Secures EU Orphan Status for ALS Drug
Pharmaust Limited (AU:NUZ) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...
manilatimes20h
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Pending FDA clearance of the IND application, Neurizon anticipates Massachusetts General Hospital (MGH) filing a protocol amendment to their IND for the HEALEY ALS Platform Trial to incorporate our ...
Yahoo Finance29d
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Provides valuable insights into the mechanism of action of NUZ-001 in ALS and strengthens promising efficacy results from the Phase 1 MEND study completed earlier this year in patients with ALS ...